A股異動 | 大參林盤初逼近跌停 實控人之一柯金龍涉嫌單位行賄罪
連鎖藥店頭部企業大參林(603233.SH)盤初逼近跌停,近期完全抹平此前升幅,最低報21.2元,總市值跌破250億元。上週五盤後公吿,其實控人之一柯金龍涉嫌單位行賄罪,已被廣東省茂名市電白區人民檢察院提起公訴。目前該案一審已開庭,正在審理,柯金龍處於拘留狀態。據悉,柯金龍與兩位哥哥柯雲峯、柯康保一起創立了大參林,“柯氏三兄弟”是大參林的控股股東、實控人。截至目前,柯金龍持有大參林20.16%的股權。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.